Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells

Wei Chien Huang, Yun Ju Chen, Long Yuan Li, Ya Ling Wei, Sheng Chieh Hsu, Shing Ling Tsai, Pei Chun Chiu, Wei Pang Huang, Ying Nai Wang, Chung Hsuan Chen, Wei Chao Chang, Wen Chang Chang, Andy Jer En Chen, Chang Hai Tsai, Mien Chie Hung

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR), an aberrantly overexpressed or activated receptor-tyrosine kinase in many cancers, plays a pivotal role in cancer progression and has been an attractive target for cancer therapy. Gefitinib and erlotinib, two EGFR-tyrosine kinase inhibitors, have been approved for nonsmall cell lung cancer. However, durable clinical efficacy of these EGFR inhibitors is severely limited by the emergence of acquired resistance. For example, the expression of breast cancer-resistant protein (BCRP/ABCG2) has been shown to confer acquired resistance of wild-type EGFR (wtEGFR)-expressing cancer cells to gefitinib. However, the underlying molecular mechanisms still remain unclear. Here, we show that wtEGFR expression is elevated in the nucleus of acquired gefitinib-resistant cancer cells. Moreover, nuclear translocation of EGFR requires phosphorylation at Ser-229 by Akt. In the nucleus, EGFR then targets the proximal promoter of BCRP/ABCG2 and thereby enhances its gene transcription. The nuclear EGFR-mediated BCRP/ABCG2 expression may contribute at least in part to the acquired resistance of wtEGFR-expressing cancer cells to gefitinib. Our findings shed light on the role of nuclear EGFR in the sensitivity of wtEGFR-expressing cancer cells to EGFR tyrosine kinase inhibitors and also deciphered a putative molecular mechanism contributing to gefitinib resistance through BCRP/ ABCG2 expression.

Original languageEnglish
Pages (from-to)20558-20568
Number of pages11
JournalJournal of Biological Chemistry
Volume286
Issue number23
DOIs
Publication statusPublished - Jun 10 2011
Externally publishedYes

Fingerprint

Phosphorylation
Epidermal Growth Factor Receptor
Breast Neoplasms
Cells
Proteins
Neoplasms
Protein-Tyrosine Kinases
gefitinib
Receptor Protein-Tyrosine Kinases
Transcription
Non-Small Cell Lung Carcinoma
Genes

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. / Huang, Wei Chien; Chen, Yun Ju; Li, Long Yuan; Wei, Ya Ling; Hsu, Sheng Chieh; Tsai, Shing Ling; Chiu, Pei Chun; Huang, Wei Pang; Wang, Ying Nai; Chen, Chung Hsuan; Chang, Wei Chao; Chang, Wen Chang; Chen, Andy Jer En; Tsai, Chang Hai; Hung, Mien Chie.

In: Journal of Biological Chemistry, Vol. 286, No. 23, 10.06.2011, p. 20558-20568.

Research output: Contribution to journalArticle

Huang, WC, Chen, YJ, Li, LY, Wei, YL, Hsu, SC, Tsai, SL, Chiu, PC, Huang, WP, Wang, YN, Chen, CH, Chang, WC, Chang, WC, Chen, AJE, Tsai, CH & Hung, MC 2011, 'Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells', Journal of Biological Chemistry, vol. 286, no. 23, pp. 20558-20568. https://doi.org/10.1074/jbc.M111.240796
Huang, Wei Chien ; Chen, Yun Ju ; Li, Long Yuan ; Wei, Ya Ling ; Hsu, Sheng Chieh ; Tsai, Shing Ling ; Chiu, Pei Chun ; Huang, Wei Pang ; Wang, Ying Nai ; Chen, Chung Hsuan ; Chang, Wei Chao ; Chang, Wen Chang ; Chen, Andy Jer En ; Tsai, Chang Hai ; Hung, Mien Chie. / Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. In: Journal of Biological Chemistry. 2011 ; Vol. 286, No. 23. pp. 20558-20568.
@article{d841bb42505a435f8111b8c406c66fc3,
title = "Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells",
abstract = "Epidermal growth factor receptor (EGFR), an aberrantly overexpressed or activated receptor-tyrosine kinase in many cancers, plays a pivotal role in cancer progression and has been an attractive target for cancer therapy. Gefitinib and erlotinib, two EGFR-tyrosine kinase inhibitors, have been approved for nonsmall cell lung cancer. However, durable clinical efficacy of these EGFR inhibitors is severely limited by the emergence of acquired resistance. For example, the expression of breast cancer-resistant protein (BCRP/ABCG2) has been shown to confer acquired resistance of wild-type EGFR (wtEGFR)-expressing cancer cells to gefitinib. However, the underlying molecular mechanisms still remain unclear. Here, we show that wtEGFR expression is elevated in the nucleus of acquired gefitinib-resistant cancer cells. Moreover, nuclear translocation of EGFR requires phosphorylation at Ser-229 by Akt. In the nucleus, EGFR then targets the proximal promoter of BCRP/ABCG2 and thereby enhances its gene transcription. The nuclear EGFR-mediated BCRP/ABCG2 expression may contribute at least in part to the acquired resistance of wtEGFR-expressing cancer cells to gefitinib. Our findings shed light on the role of nuclear EGFR in the sensitivity of wtEGFR-expressing cancer cells to EGFR tyrosine kinase inhibitors and also deciphered a putative molecular mechanism contributing to gefitinib resistance through BCRP/ ABCG2 expression.",
author = "Huang, {Wei Chien} and Chen, {Yun Ju} and Li, {Long Yuan} and Wei, {Ya Ling} and Hsu, {Sheng Chieh} and Tsai, {Shing Ling} and Chiu, {Pei Chun} and Huang, {Wei Pang} and Wang, {Ying Nai} and Chen, {Chung Hsuan} and Chang, {Wei Chao} and Chang, {Wen Chang} and Chen, {Andy Jer En} and Tsai, {Chang Hai} and Hung, {Mien Chie}",
year = "2011",
month = "6",
day = "10",
doi = "10.1074/jbc.M111.240796",
language = "English",
volume = "286",
pages = "20558--20568",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "23",

}

TY - JOUR

T1 - Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells

AU - Huang, Wei Chien

AU - Chen, Yun Ju

AU - Li, Long Yuan

AU - Wei, Ya Ling

AU - Hsu, Sheng Chieh

AU - Tsai, Shing Ling

AU - Chiu, Pei Chun

AU - Huang, Wei Pang

AU - Wang, Ying Nai

AU - Chen, Chung Hsuan

AU - Chang, Wei Chao

AU - Chang, Wen Chang

AU - Chen, Andy Jer En

AU - Tsai, Chang Hai

AU - Hung, Mien Chie

PY - 2011/6/10

Y1 - 2011/6/10

N2 - Epidermal growth factor receptor (EGFR), an aberrantly overexpressed or activated receptor-tyrosine kinase in many cancers, plays a pivotal role in cancer progression and has been an attractive target for cancer therapy. Gefitinib and erlotinib, two EGFR-tyrosine kinase inhibitors, have been approved for nonsmall cell lung cancer. However, durable clinical efficacy of these EGFR inhibitors is severely limited by the emergence of acquired resistance. For example, the expression of breast cancer-resistant protein (BCRP/ABCG2) has been shown to confer acquired resistance of wild-type EGFR (wtEGFR)-expressing cancer cells to gefitinib. However, the underlying molecular mechanisms still remain unclear. Here, we show that wtEGFR expression is elevated in the nucleus of acquired gefitinib-resistant cancer cells. Moreover, nuclear translocation of EGFR requires phosphorylation at Ser-229 by Akt. In the nucleus, EGFR then targets the proximal promoter of BCRP/ABCG2 and thereby enhances its gene transcription. The nuclear EGFR-mediated BCRP/ABCG2 expression may contribute at least in part to the acquired resistance of wtEGFR-expressing cancer cells to gefitinib. Our findings shed light on the role of nuclear EGFR in the sensitivity of wtEGFR-expressing cancer cells to EGFR tyrosine kinase inhibitors and also deciphered a putative molecular mechanism contributing to gefitinib resistance through BCRP/ ABCG2 expression.

AB - Epidermal growth factor receptor (EGFR), an aberrantly overexpressed or activated receptor-tyrosine kinase in many cancers, plays a pivotal role in cancer progression and has been an attractive target for cancer therapy. Gefitinib and erlotinib, two EGFR-tyrosine kinase inhibitors, have been approved for nonsmall cell lung cancer. However, durable clinical efficacy of these EGFR inhibitors is severely limited by the emergence of acquired resistance. For example, the expression of breast cancer-resistant protein (BCRP/ABCG2) has been shown to confer acquired resistance of wild-type EGFR (wtEGFR)-expressing cancer cells to gefitinib. However, the underlying molecular mechanisms still remain unclear. Here, we show that wtEGFR expression is elevated in the nucleus of acquired gefitinib-resistant cancer cells. Moreover, nuclear translocation of EGFR requires phosphorylation at Ser-229 by Akt. In the nucleus, EGFR then targets the proximal promoter of BCRP/ABCG2 and thereby enhances its gene transcription. The nuclear EGFR-mediated BCRP/ABCG2 expression may contribute at least in part to the acquired resistance of wtEGFR-expressing cancer cells to gefitinib. Our findings shed light on the role of nuclear EGFR in the sensitivity of wtEGFR-expressing cancer cells to EGFR tyrosine kinase inhibitors and also deciphered a putative molecular mechanism contributing to gefitinib resistance through BCRP/ ABCG2 expression.

UR - http://www.scopus.com/inward/record.url?scp=79957982003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957982003&partnerID=8YFLogxK

U2 - 10.1074/jbc.M111.240796

DO - 10.1074/jbc.M111.240796

M3 - Article

VL - 286

SP - 20558

EP - 20568

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 23

ER -